Marker Therapeutics (MRKR) Other Accumulated Expenses (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Other Accumulated Expenses data on file, last reported at $1.0 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $1.0 million, up 143.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 143.41% YoY), and the FY2024 annual result was $1.7 million, up 28.61% from the prior year.
• Other Accumulated Expenses climbed to $1.0 million in Q1 2026 per MRKR's latest filing, from $328315.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $1.7 million in Q4 2024 and troughed at $38000.0 in Q4 2022.
• A 5-year average of $545993.1 and a median of $341140.0 in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses sank 84.8% in 2022, then surged 3400.0% in 2023.
• A 5-year view of Other Accumulated Expenses shows it stood at $38000.0 in 2022, then surged by 3400.0% to $1.3 million in 2023, then increased by 28.61% to $1.7 million in 2024, then slumped by 80.81% to $328315.0 in 2025, then soared by 204.96% to $1.0 million in 2026.
• Business Quant data shows MRKR's Other Accumulated Expenses at $1.0 million in Q1 2026, $328315.0 in Q3 2025, and $656631.0 in Q2 2025.